Form 4: Lexeo CDO Reports RSU Vesting and Tax-Related Stock Sales
Insider Transaction Report
Lexeo Therapeutics' Chief Development Officer, See Tai Sandi, reported the acquisition of common stock and subsequent sales to cover tax obligations related to Restricted Stock Units.
Summary
- See Tai Sandi, Chief Development Officer of Lexeo Therapeutics, Inc. (LXEO), reported transactions involving the company's common stock.
- On October 15, 2025, 10,890 shares of common stock were acquired at a price of $0, likely representing the vesting of Restricted Stock Units (RSUs).
- Following this acquisition, the beneficial ownership of common stock increased to 69,750 shares.
- On October 17, 2025, a total of 3,888 shares of common stock were disposed of in two separate transactions to cover tax obligations arising from the RSU release.
- The first sale involved 3,844 shares at a weighted average price of $8.935, with trades ranging from $8.53 to $9.52.
- The second sale involved 44 shares at a weighted average price of $9.561, with trades ranging from $9.53 to $9.59.
- After these transactions, See Tai Sandi's direct beneficial ownership of common stock stands at 65,862 shares, which includes 49,138 unvested RSUs.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing reports routine compensation-related transactions (RSU vesting and subsequent tax-related sales) by an executive, which are common and expected events.
Positives
- The acquisition of 10,890 shares at $0 indicates the vesting of Restricted Stock Units, representing compensation for the Chief Development Officer.
- The remaining beneficial ownership of 65,862 shares, including 49,138 RSUs, demonstrates continued alignment of the Chief Development Officer's interests with shareholders.
Negatives
- The disposition of 3,888 shares, while for tax obligations, reduces the Chief Development Officer's direct equity stake in the company.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This insider transaction report is specific to an individual officer's compensation and tax obligations and does not provide broader insights into industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: The reduction in the Chief Development Officer's direct shareholding is minimal and for tax purposes, unlikely to significantly impact shareholder sentiment.
- Employees: The vesting of RSUs is a standard form of executive compensation, reflecting the company's compensation practices.
Key Dates
| Date | Description |
|---|---|
| 10/15/2025 | Date of acquisition of 10,890 shares of common stock. |
| 10/17/2025 | Date of disposition of 3,844 shares of common stock to cover tax obligations. |
| 10/17/2025 | Date of disposition of 44 shares of common stock to cover tax obligations. |
| 10/17/2025 | Date the Form 4 was signed by the Attorney-in-Fact. |
Keywords
Lexeo Therapeutics, LXEO, Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Sale, Tax Obligations, Chief Development Officer, See Tai Sandi
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.